Carboplatin: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
imported>Robert Badgett
No edit summary
Line 1: Line 1:
In [[oncology]], '''carboplatin''' is an "organoplatinum compound that possesses antineoplastic activity."<ref>{{MeSH}}</ref>
In [[oncology]], '''carboplatin''' is an "organoplatinum compound that possesses antineoplastic activity."<ref>{{MeSH}}</ref>
As compared to [[cisplatin]], carboplatin has equal (lung cancer, ovarian cancer) or less (germ cell tumors, bladder cancer, head and neck cancer) efficacy but less [[drug toxicity]].<ref name="pmid9541678">{{cite journal| author=Lokich J, Anderson N| title=Carboplatin versus cisplatin in solid tumors: an analysis of the literature. | journal=Ann Oncol | year= 1998 | volume= 9 | issue= 1 | pages= 13-21 | pmid=9541678
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=9541678 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>


==History==
==History==
In the United States, it was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) by the FDA in 1989.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=019880 Drugs@FDA]. U S Food and Drug Administration</ref> A generic version was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2003.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=076039 Drugs@FDA]. U S Food and Drug Administration</ref>
In the United States, it was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) by the FDA in 1989.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=019880 Drugs@FDA]. U S Food and Drug Administration</ref> A generic version was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2003.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=076039 Drugs@FDA]. U S Food and Drug Administration</ref>
As compared to [[cisplatin]], carboplatin has equal (lung cancer, ovarian cancer) or less (germ cell tumors, bladder cancer, head and neck cancer) efficacy but less drug [[toxicity]].<ref name="pmid9541678">{{cite journal| author=Lokich J, Anderson N| title=Carboplatin versus cisplatin in solid tumors: an analysis of the literature. | journal=Ann Oncol | year= 1998 | volume= 9 | issue= 1 | pages= 13-21 | pmid=9541678
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=9541678 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>


==External links==
==External links==

Revision as of 15:40, 8 September 2009

In oncology, carboplatin is an "organoplatinum compound that possesses antineoplastic activity."[1]


As compared to cisplatin, carboplatin has equal (lung cancer, ovarian cancer) or less (germ cell tumors, bladder cancer, head and neck cancer) efficacy but less drug toxicity.[2]

History

In the United States, it was approved with a New Drug Application (NDA) by the FDA in 1989.[3] A generic version was approved with a Abbreviated New Drug Application (ANDA) in 2003.[4]

External links

The most up-to-date information about Carboplatin and other drugs can be found at the following sites.


References

  1. Anonymous (2024), Carboplatin (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Lokich J, Anderson N (1998). "Carboplatin versus cisplatin in solid tumors: an analysis of the literature.". Ann Oncol 9 (1): 13-21. PMID 9541678.
  3. Drugs@FDA. U S Food and Drug Administration
  4. Drugs@FDA. U S Food and Drug Administration